Novel copper metal organic framework nanoparticles Cu-MOF-NPs (C1) were prepared via two simple alternative methods and confirmed by analytical characterization using mass, IR, Raman, XRD spectrum, HR-TEM and TGA-DSC. Mass spectroscopy revealed the molecular ion peak at 647 m/z for the monomeric unit structure n[Cu(AIP)2(PIY)(H2O)2]·4H2O, the presence of which was further supported by mass fragmentation. The Raman spectrum revealed two separate peaks corresponding to D and G bands of carbon in the structure of C1. Moreover, TGA-DSC showed the presence of CuO. XRD data were typically consistent with Raman and TGA-DSC data. In addition, HR-TEM revealed that the morphology of the C1 nanoparticles is uniform with well-distributed elliptical/spherical particles with a size range from 7 to 19 nm. The spectrophotometric and biological activity studies based on Cu-MOF-NPs were analyzed. The results indicated that Cu-MOF-NPs (C1) were successfully used as biosensors for the assessment of the triiodothyronine hormone (T3). The calibration plot was achieved over the concentration range of 40.0–100.0 ng dl−1 T3 with limits of detection (LOD) and quantitation (LOQ) of 1.46 and 4.85 ng dl−1, respectively, and a correlation coefficient (r) of 0.973. Moreover, the Cu-MOF-NPs (C1) show more enhanced biological activity against various pathogens (five strains of bacteria: Gram positive and Gram negative) when compared to an antibacterial agent and the effectiveness of Cu-MOF-NPs increases with increasing particle dose. The interactions of MOF-NPs (C1) with the biological targets were studied.
1 March 2016 in Beni-Suef University Journal of Basic and Applied Sciences
A Schiff base ligand 1 was prepared from condensation of salicyaldehyde with 2-amino-4-phenyl-5-methyl thiazole. The ligand forms complexes with CoII, NiII, CuII, and ZnII in good yield. The synthesized compounds were characterized by elemental analysis, magnetic susceptibility, molar conductance, infrared spectra, 1H and 13C NMR, mass, electronic absorption and ESR spectroscopy. The anticancer activity of the synthesized compounds was studied against different human tumor cell lines: breast cancer MCF-7, liver cancer HepG2, lung carcinoma A549 and colorectal cancer HCT116 in comparison with the activity of doxorubicin as a reference drug. The study showed that ZnII complex showed potent inhibition against human TRK in the four cell lines (HepG2, MCF7, A549, HCT116) by the ratio 80, 70, 61 and 64% respectively as compared to the inhibition in the untreated cells. Moreover, the molecular docking into TRK (PDB: 1t46) was done for the optimization of the aforementioned compounds as potential TRK inhibitors